{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.22","value":"-5.0"},{"groupId":"OG001","spread":"19.50","value":"-4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.38","value":"-3.9"},{"groupId":"OG001","spread":"21.50","value":"-7.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 5, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.19","value":"-6.1"},{"groupId":"OG001","spread":"19.76","value":"-8.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.54","value":"-3.5"},{"groupId":"OG001","spread":"20.01","value":"-8.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Cycle 9, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.92","value":"-1.5"},{"groupId":"OG001","spread":"18.46","value":"-7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.57","value":"-3.2"},{"groupId":"OG001","spread":"22.85","value":"-8.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"Cycle 13, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.72","value":"-2.3"},{"groupId":"OG001","spread":"22.27","value":"-7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Cycle 15, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.23","value":"-1.8"},{"groupId":"OG001","spread":"19.90","value":"-8.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.30","value":"-2.5"},{"groupId":"OG001","spread":"19.35","value":"-7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 19, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.81","value":"-1.5"},{"groupId":"OG001","spread":"20.43","value":"-8.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 21, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.32","value":"-3.4"},{"groupId":"OG001","spread":"20.53","value":"-7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.28","value":"-3.8"},{"groupId":"OG001","spread":"23.95","value":"0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 25, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.69","value":"-8.6"},{"groupId":"OG001","spread":"18.44","value":"-3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Cycle 27, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.25","value":"-8.7"},{"groupId":"OG001","spread":"19.81","value":"-4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.98","value":"-2.8"},{"groupId":"OG001","spread":"18.56","value":"2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 31, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.76","value":"-4.0"},{"groupId":"OG001","spread":"23.64","value":"-4.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 33, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.64","value":"-7.0"},{"groupId":"OG001","spread":"18.70","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.49","value":"-7.5"},{"groupId":"OG001","spread":"14.78","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 37, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.80","value":"-10.1"},{"groupId":"OG001","spread":"10.18","value":"8.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 39, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.65","value":"-13.0"},{"groupId":"OG001","spread":"23.09","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.12","value":"-7.8"},{"groupId":"OG001","spread":"18.86","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 43, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.33","value":"-1.3"},{"groupId":"OG001","spread":"18.86","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 45, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.40","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.85","value":"-11.8"},{"groupId":"OG001","spread":"21.52","value":"-10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Final visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as \"not at all\" and 4 as \"very much.\" The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"MEAN","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization; participants who have both baseline and post-baseline values are included in the analysis at each visit","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 3 (Cycles 1 - 8 are 21 days, Cycles 9 and beyond are 35 days) through Cycle 47, collected on Day 1 of every other cycle and at the Treatment Completion Visit (TCV) while participant is on treatment","title":"Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"units on a scale"}